Luteinising hormone releasing hormone analogues in the treatment of prostate cancer

REFERENCES

• MORRIS MJ, SCHER HI: Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surg. Oncol. (2002) 11:13–23.
   PubMed Web of Science ®Google Scholar
• MAJEED A, BABB P, JONES J, QUINN M: Trends in prostate cancer incidence, mortality and survival in England and Wales (1971-1998). What. (2000) 85:1058–1062.
   Google Scholar
• PALMER JF: The Works &John Hunter ER.S. with notes. Longman, London, UK (1837).
   Google Scholar
• WHITE WJ: Surgical removal of the hypertrophied prostate. Ann. Surg. (1893):152.
   PubMedGoogle Scholar
• DEMING CL, JENKINS RH, VAN WAGENER G: Further studies in the endocrinology relationships of prostatic hypertrophy. Urol. (1935):34.
   Google Scholar
• MOORE RA, MCCLELLAN AM: Histological study of the effect of the sex hormones on the human prostate. 1 Ural. (1938) 40:641.
   Google Scholar
• HUGGINS C, STEPHENS RA: The effects of castration on benign hypertrophy of the prostate in man.' Urol. (1940) 43:105.
   Google Scholar
• STAMEY TA, YANG N, HAY AR, MCNEAL JE, FREIHA FS, REDWINE E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl. .1. Med. (1987) 317:909–916.
   Google Scholar
• ABRAHAMSSON PA: Treatment of locally advanced prostate cancer - a new role for antiandrogen monotherapy? Eur. Urol. (2001) 39\(Suppl. 1):22–28.
   Google Scholar
• HUGGINS CB, HODGES CV: Studies on Prostate Cancer: 1. The effects of castration, of eostrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. (1941) 1:203.
   Google Scholar
• HUGGINS C, STEPHENS RC, HODGES CV: Studies on prostate cancer: 2. The effects of castration on advanced carcinoma of the prostate. Arch. Surg. (1941) 43:209.
   Google Scholar
• Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg. Cynecol. Obstet. (1967) 124:1011–1017.
   PubMedGoogle Scholar
• VOGELZANG NJ, CHODAK GW, SOLOWAY MS et al: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology (1995) 46:220–226.
   PubMed Web of Science ®Google Scholar
• LABRIE F, BELANGER A, CUSAN L et al.: Antifertility effects of LHRH agonists in the male. J. Andra (1980) 1:209–228.
   Google Scholar
• JONES TH, JUSTICE S, PRICE A, CHAPMAN K: Interleukin-6 secreting human pituitary adenomas in vitro. j Clin. Endocrinol. Metab. (1991) 73:207–209.
   PubMedGoogle Scholar
• TOLIS G, ACKMAN D, STELLOS A et al.: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA (1982) 79:1658–1662.
   PubMed Web of Science ®Google Scholar
• WAYMONT B, LYNCH TH, DUNN JA et al.: Phase III randomised study of Zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br. .1. Urol. (1992) 69:614–620.
   Google Scholar
• SCHALLY AV, COMARU-SCHALLY AM,PLONOWSKI A, NAGY A, HALMOS G, REKASI Z: Peptide analogs in the therapy of prostate cancer. Prostate (2000) 45:158–166.
   PubMed Web of Science ®Google Scholar
• Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl. J. Med. (1984) 311:1281–1286.
   PubMedGoogle Scholar
• LABRIE F: Intracrinology. Mol. Cell Endocrinol. (1991) 78:C113–C118.
   Google Scholar
• STEINBERG GD, ISAACS JT: Pharmacological approaches to the management of metastatic prostatic cancer. In: Cancer Chemotherapy (Hickman JA & Hitton TR, Eds). Blackwell Scientific Publications, Oxford, UK (1993):322–341.
   Google Scholar
• VARENHORST E, WALLENTIN L, CARLSTROM K: The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand. .1. Urol. Nephrol. (1982) 16:31–36.
   PubMed Web of Science ®Google Scholar
• Prostate cancer and gonadorelin analogues: 8.3.4.2. Brit. National Formulary 43 (2002).
   Google Scholar
• BAUS Section of Oncology. Analyses of minimum data set for urological cancers January 1st - 31st December 2000. The British Association of Urological Surgeons (2001).
   Google Scholar
• Prescription cost analysis data (England 2001). Department of Health, UK (2001).
   Google Scholar
• BEESE G: Randomised cross over trial to assess the tolerability of LHRH analogue administration. British Association of Urological Nurses Annual General Meeting (2000).
   Google Scholar
• SMALL EJ: Prostate cancer, incidence, management and outcomes. Drugs Aging (1998) 13:71–81.
   PubMedGoogle Scholar
• DIJKMAN GA, DEBRUYNE FM, FERNANDEZ DM et al.: A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group. Eur: Urol (1995) 27:43–46.
   Google Scholar
• Maximum androgen blockade in advancedprostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (2000) 355:1491–1498.
   Google Scholar
• COCKSHOTT ID: Clinical pharmacokinetics of goserelin. Chit. Pharmacokinet. (2000) 39:27–48.
   PubMed Web of Science ®Google Scholar
• PERREN TJ, CLAYTON RN, BLACKLEDGE G et al.: Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI (1186)30 (Zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Cancer Chemother. PharmacoL (1986) 18:39–43.
   PubMed Web of Science ®Google Scholar
• AHMANN FR, CITRIN DL, DEHAAN HA et al.: Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J. Chit. OncoL (1987) 5:912–917.
   PubMed Web of Science ®Google Scholar
• JOHNS WD, GARNICK MB, KAPLAN WD: Leuprolide therapy for prostate cancer. An association with scintigraphic 'flare' on bone scan. Clin. Nucl. Med. (1990) 15:485–487.
   Google Scholar
• SMITH JA Jr: Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue. Frog. Clin. Biol. Res. (1985) 185A:279–285.
   PubMedGoogle Scholar
• LABRIE F, DUPONT A, BELANGER A, LACHANCE R: Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. Ural. (1987) 138:804–806.
   PubMed Web of Science ®Google Scholar
• LABRIE F, DUPONT A, BELANGER A, EMOND J, MONFETTE G: Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc. Natl. Acad. Sci. USA (1984) 81:3861–3863.
   PubMedGoogle Scholar
• Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with (3283) deaths in (5710) patients. Prostate Cancer Trialists' Collaborative Group. Lancet (1995) 346:265–269.
   Google Scholar
• CAUBET JF, TOSTESON TD, DONG EW et al.: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology (1997) 49:71–78.
   PubMed Web of Science ®Google Scholar
• SEIDENFELD J, SAMSON DJ, HASSELBLAD V et al.: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. (2000) 132:566–577.
   PubMed Web of Science ®Google Scholar
• SAROSDY ME SCHELLHAMMER PF, SOLOWAY MS et al.: Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. What. (1999) 83:801–806.
   Google Scholar
• CHODAK GW, VOGELZANG NJ, CAPLAN RJ, SOLOWAY M, SMITH JA: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA (1991) 265:618–621.
   PubMed Web of Science ®Google Scholar
• Prostate cancer and gonadorelin analogues:8.3.4.2. Brit. National Formulary 43 (2002).
   Google Scholar
• IVERSEN P, TYRRELL CJ, KAISARY AV et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. UroL (2000) 164:1579–1582.
   Google Scholar
• TYRRELL CJ: Gynaecomastia: aetiology and treatment options. Prost. Cancer. Prost. Dis. (1999) 2:167.
   PubMedGoogle Scholar
• DENIS LJ, KEUPPENS F, SMITH PH et al.: Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur. Ural. (1998) 33:144–151.
   Google Scholar
• BOLLA M, GONZALEZ D, WARDE P et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl. J. Med. (1997) 337:295–300.
   PubMed Web of Science ®Google Scholar
• PILEPICH MV, WINTER K, JOHN MJ et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol Biol. Phys. (2001) 50:1243–1252.
   PubMed Web of Science ®Google Scholar
• LILLEBY W, FOSSA SD, KNUTSEN BH,ABILDGAARD A, SKOVLUND E, LIEN HH: Computed tomography/ magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother. Oncol (2000) 57:195–200.
   PubMed Web of Science ®Google Scholar
• KUCWAY R, VICINI F, HUANG R, STROMBERG J, GONZALEZ J, MARTINEZ A: Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. Ural. (2002) 167:2443–2447.
   PubMedGoogle Scholar
• DEBRUYNE FM, WITJES WP: Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Ma Ural. (2000) 4:251–256.
   Google Scholar
• THEYER G, HAMILTON G: Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology (1998) 52:353–359.
   PubMed Web of Science ®Google Scholar
• ABRAHAMSSON PA: Intermittent androgen suppression. Too good to be true? Scand. I Ural. NephroL Stipp]. (1999) 203:45–49.
   Google Scholar
• EGAWA S, TAKASHIMA R, MATSUMOTO K, MIZOGUCHI H, KUWAO S, BABA S: A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. fpn. Oncol (2000) 30:21–26.
   Google Scholar
• GONCALVES F, MIKLOSI M, BREZA J: Intermittent androgen suppression for locally advanced and metastatic prostate cancer. Eur. Ural. (2000) 38(4):503.
   Google Scholar
• KAISARY AV, TYRRELL CJ, PEELING WB, GRIFFITHS K: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br: J. Ural. (1991) 67:502–508.
   PubMedGoogle Scholar
• DANIELL HW, DUNN SR, FERGUSON DW, LOMAS G, NIAZI Z, STRATTE PT: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Ural. (2000) 163:181–186.
   PubMed Web of Science ®Google Scholar
• WEI JT, GROSS M, JAFFE CA et al.: Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology (1999) 54:607–611.
   PubMed Web of Science ®Google Scholar